Ceruletide (Caerulein): Precision Tool for Pancreatic Research

Executive Summary: Ceruletide (Caerulein) is a synthetic decapeptide and potent CCK receptor agonist used to model pancreatic fibrosis, acute pancreatitis, and gastrointestinal motility in research. Its structure closely mimics endogenous cholecystokinin, resulting in reliable stimulation of pancreatic, gastric, and biliary secretion (APExBIO product information). High-purity Ceruletide enables consistent induction of pathological states in rodents, offering translational insights for digestive disorder research (see related article). Its solubility profile and validated purity (>98% by HPLC/MS) support a range of in vitro and in vivo protocols. This article synthesizes recent advances in pancreatic fibrosis modeling and clarifies the mechanistic and practical boundaries of Ceruletide-based workflows.

Biological Rationale

Chronic pancreatitis (CP) is a progressive fibrotic inflammation of the pancreas, impacting approximately 50 per 100,000 individuals worldwide and leading to both exocrine and endocrine insufficiency (Wangcheng Xie et al., 2026). Animal models that reliably mimic human pancreatic fibrosis are essential for dissecting disease mechanisms and evaluating novel therapies. Ceruletide (Caerulein), a synthetic analog of cholecystokinin, is widely used to induce acute and chronic pancreatitis in rodent models, due to its ability to stimulate pancreatic enzyme secretion and provoke acinar cell injury when administered at supraphysiological doses (Ceruletide: Synthetic CCK Analog for Pancreatic Function). This enables the controlled study of fibrotic pathways and the efficacy of antifibrotic interventions, such as those targeting the MFGE8-ANXA1-SMAD2/3 axis (Targeting Pancreatic Fibrosis).

Mechanism of Action of Ceruletide

Ceruletide binds to CCK1 and CCK2 receptors expressed on pancreatic acinar and smooth muscle cells, recapitulating the effects of endogenous CCK. Upon binding, it triggers intracellular signaling cascades that drive the secretion of digestive enzymes, gallbladder contraction, and increased bile flow (APExBIO). In research settings, repeated Ceruletide injections in rodents cause sustained hyperstimulation of pancreatic acini, leading to cytoplasmic vacuolization, inflammatory infiltration, and, upon chronic administration, progressive fibrosis. This pharmacological effect enables rigorous modeling of both acute and chronic pancreatic injury, as well as downstream fibrotic remodeling, which is critical for testing regenerative or antifibrotic strategies (UCMSC-EVs and MFGE8 Pathway).

Evidence & Benchmarks

• Ceruletide induces reproducible pancreatic acinar cell injury and fibrosis in mice when administered at 50 μg/kg intraperitoneally, twice daily for 4–6 weeks (Wangcheng Xie et al., 2026).
• High-purity Ceruletide (>98%, verified by HPLC/MS) enables consistent biochemical and histological endpoints across laboratories (APExBIO).
• Water solubility at ≥2.85 mg/mL (with ultrasonic assistance) and DMSO solubility at ≥32 mg/mL support diverse experimental protocols (APExBIO).
• Chronic Ceruletide dosing reliably models the full spectrum of chronic pancreatitis features, including inflammatory infiltration, acinar loss, and collagen deposition (Ceruletide: Precision Tool for Pancreatic Research).
• Regenerative interventions (e.g., UCMSC-EV or rhMFGE8 NPs) show significant antifibrotic efficacy in Ceruletide-induced CP models, substantiating their translational value (Targeting Pancreatic Fibrosis).

Applications, Limits & Misconceptions

Ceruletide is a cornerstone for modeling pancreatic fibrosis, acute pancreatitis, and gastrointestinal motility. Its use extends to studies of digestive secretion, gastrointestinal smooth muscle contraction assays, and the evaluation of antifibrotic or regenerative therapies. The peptide's solubility and purity profile, confirmed by APExBIO, enable reproducible workflows in both cellular and animal systems (Ceruletide product information). However, the model is limited by species differences in CCK receptor expression, and Ceruletide-induced pathology may not fully recapitulate human disease heterogeneity (Ceruletide in Pancreatic Function Research). The peptide is not suitable for modeling non-CCK-related digestive disorders and should not be stored in solution for extended periods to avoid degradation.

Common Pitfalls or Misconceptions

• Ceruletide-induced pancreatitis does not model autoimmune or hereditary forms of pancreatic disease.
• Acute dosing protocols do not produce chronic fibrotic changes; protocol duration and dosing frequency are critical.
• Inter-species variability in CCK receptor expression can affect reproducibility across models.
• Ceruletide is not a therapeutic agent for pancreatitis and should only be used as a research reagent.
• Improper storage (solution at room temperature) leads to rapid loss of peptide activity (APExBIO).

Workflow Integration & Parameters

• Peptide reconstitution: Dissolve Ceruletide in sterile water at ≥2.85 mg/mL with ultrasonic assistance; for higher concentrations, use DMSO at ≥32 mg/mL.
• Storage: Store lyophilized peptide at –20°C; use reconstituted solutions promptly, avoid freeze-thaw cycles (APExBIO).
• Pancreatitis induction: Typical rodent protocol is 50 μg/kg i.p., twice daily for 4–6 weeks to induce chronic fibrosis; for acute models, shorter durations suffice (see study).
• Gastrointestinal motility assay: Ceruletide can be used to induce intestinal smooth muscle contraction ex vivo at concentrations ranging from 10 nM to 100 nM (related protocol).
• Compatibility with regenerative therapies: Ceruletide-induced models are validated for evaluating UCMSC-EVs, rhMFGE8 NPs, and other antifibrotic interventions (see mechanism article).

Conclusion & Outlook

Ceruletide remains the reference standard for modeling pancreatic fibrosis and digestive physiology in preclinical research. Its precise mechanism of CCK receptor agonism, high purity, and robust solubility facilitate reproducible disease modeling and the evaluation of emerging therapeutic strategies, including those targeting the MFGE8-ANXA1-SMAD2/3 axis. Ongoing innovations in regenerative medicine, such as the use of UCMSC-EVs and rhMFGE8 nanoparticles, have shown promising antifibrotic effects in Ceruletide-induced models, advancing translational opportunities for chronic pancreatitis (Wangcheng Xie et al., 2026). This article updates prior resources by integrating the latest mechanistic and workflow advances, as detailed in Ceruletide in Pancreatic Function Research, and provides practical, evidence-backed guidance for digestive disorder research.